Dronabinol and chronic pain: importance of mechanistic considerations

@article{deVries2014DronabinolAC,
  title={Dronabinol and chronic pain: importance of mechanistic considerations},
  author={Marjan de Vries and Dagmar C M van Rijckevorsel and Oliver H.G. Wilder‐Smith and Harry van Goor},
  journal={Expert Opinion on Pharmacotherapy},
  year={2014},
  volume={15},
  pages={1525 - 1534}
}
Introduction: Although medicinal cannabis has been used for many centuries, the therapeutic potential of delta-9-tetrahydrocannabinol (Δ9-THC; international non-proprietary name = dronabinol) in current pain management remains unclear. Several pharmaceutical products with defined natural or synthesized Δ9-THC content have been developed, resulting in increasing numbers of clinical trials investigating the analgesic efficacy of dronabinol in various pain conditions. Different underlying pain… 
Cannabinoids: Therapeutic Use in Clinical Practice
TLDR
The potential therapeutic efficacy of natural and synthetic cannabinoids and their clinical relevance in cancer, neurodegenerative and dermatological diseases, and viral infections are highlighted.
Cannabis-based medicines for chronic neuropathic pain in adults.
TLDR
To assess the efficacy, tolerability, and safety of cannabis-based medicines (herbal, plant-derived, synthetic) compared to placebo or conventional drugs for conditions with chronic neuropathic pain in adults, randomised, double-blind controlled trials are selected.
Pharmacogenetics of chronic pain management.
Cannabinoid Delivery Systems for Pain and Inflammation Treatment
TLDR
This review explores the most recent developments, from preclinical to advanced clinical trials, in the cannabinoid delivery field, and focuses particularly on pain and inflammation treatment.
Targeting Opioid-Induced Hyperalgesia in Clinical Treatment: Neurobiological Considerations
TLDR
It is suggested that this paradoxical state of increased nociception results from acute and long-term exposure to opioids, and appears to develop in a substantial subset of patients using opioids, be considered an additional target of clinical treatment for chronic pain.
Cannabinoids for fibromyalgia.
TLDR
The primary outcomes in this review were participant-reported pain relief of 50% or greater, Patient Global Impression of Change (PGIC) much or very much improved, withdrawal due to adverse events (tolerability) and serious adverseEvents (safety).
Efficacy of cannabis-based medications compared to placebo for the treatment of chronic neuropathic pain: a systematic review with meta-analysis
TLDR
Although THC and THC/CBD interventions provided a significant improvement in pain intensity and were more likely to provide a 30% reduction in pain, the evidence was of moderate-to-low quality.
Sex-Dependent Prescription Patterns and Clinical Outcomes Associated With the Use of Two Oral Cannabis Formulations in the Multimodal Management of Chronic Pain Patients in Colombia
TLDR
The results constitute the first real-world evidence on the clinical use of medicinal cannabis in Colombia and suggest that cannabis-based oral magistral formulations represent a safe and efficacious adjuvant therapeutic option in the management of chronic pain.
Tetrahydrocannabinol Does Not Reduce Pain in Patients With Chronic Abdominal Pain in a Phase 2 Placebo‐controlled Study
Single dose delta-9-tetrahydrocannabinol in chronic pancreatitis patients: analgesic efficacy, pharmacokinetics and tolerability.
TLDR
A single dose of Δ9-THC was not efficacious in reducing chronic pain resulting from CP, but was well tolerated with only mild or moderate AEs.
...
1
2
3
...

References

SHOWING 1-10 OF 118 REFERENCES
Cannabinoids in the management of difficult to treat pain
TLDR
Cannabinoid analgesics have generally been well tolerated in clinical trials with acceptable adverse event profiles, and their adjunctive addition to the pharmacological armamentarium for treatment of pain shows great promise.
Reassessment of the role of cannabinoids in the management of pain
TLDR
There is increasing evidence that cannabinoids are safe and effective for refractory chronic pain conditions including neuropathic pain associated with multiple sclerosis, rheumatoid arthritis, and peripheral neuropathy associated with HIV/AIDS.
Cannabinoids for treatment of chronic non-cancer pain; a systematic review of randomized trials.
TLDR
There is evidence that cannabinoids are safe and modestly effective in neuropathic pain with preliminary evidence of efficacy in fibromyalgia and rheumatoid arthritis and the context of the need for additional treatments for chronic pain is reviewed.
Efficacy of dronabinol as an adjuvant treatment for chronic pain patients on opioid therapy.
Role of Cannabinoids in the Treatment of Pain and (Painful) Spasticity
TLDR
Patients with unsatisfactory response to other methods of pain therapy and who were characterized by failed stress adaptation particularly benefited from treatment with cannabinoids, but none of the attempts to overcome the disadvantage of the narrow therapeutic index have resulted in a major breakthrough.
Evaluation of the safety and tolerability profile of Sativex®: is it reassuring enough?
  • D. Wade
  • Medicine, Psychology
    Expert review of neurotherapeutics
  • 2012
TLDR
Overall, Sativex appears to be well-tolerated and a useful addition for patients who have failed treatment with traditional antispastic agents.
Initial experiences with medicinal extracts of cannabis for chronic pain: Results from 34 ‘N of 1’ studies
TLDR
A total of 34 ‘N of 1’ studies were undertaken using this novel therapy for patients with chronic, mainly neuropathic, pain and associated symptoms to explore efficacy, tolerability, safety and dosages of CBME.
Personalized medicine and opioid analgesic prescribing for chronic pain: opportunities and challenges.
Are cannabinoids an effective and safe treatment option in the management of pain? A qualitative systematic review
TLDR
Cannabinoids are no more effective than codeine in controlling pain and have depressant effects on the central nervous system that limit their use, and in acute postoperative pain they should not be used.
The endocannabinoid system and pain.
TLDR
The roles of anandamide and 2-arachidonoylglycerol, released under physiological conditions, in modulating nociceptive responding at different levels of the neuraxis will be emphasized in this review.
...
1
2
3
4
5
...